Abstract:Abstract Background: Reaching the HbA1c target and keeping the euglycemic state are major challenges in the management of individuals with diabetes. Given the high rate of failure of oral antidiabetic drugs (OADs) to control the glycemic state of individuals with type-2 diabetes mellitus (T2DM), other new options have emerged to replace the traditional treatments in such cases. Second-generation basal insulin glarginehas proven its safety and efficacy in improving glycemic control in individuals with uncontrolled T2DM in multiple randomized clinical trials (RCTs). Aim of Study: This study aims to assess the effectiveness and safety of insulin glargine 300U/mL (Gla-300) when added to OADs and titrated to individualized goals in real-world practice. Patient and Methods: The ATOS study was a prospective, observational, international, multicenter study to collect information on 4422 individuals with T2DMinitiating Gla-300 across 18 countries in different geographical regions, and which routinely assessed glycated hemoglobin (HbA1c) at least every 6 months (NCT03703869). Our posthocsub group analysis is a part of this large-scale multinational study that analyzed the data collected from Egypt, one of the countries representing the South African region, to assess the real-world effectiveness of Gla-300 in Egyptian individuals with T2DM. The primary outcomes include an assessment of the effective-ness of Gla-300 in achieving glycemic goals measured by HbA1c after 6 months. The secondary objectives include effectiveness and safety during the extended follow-up period (12 months). Results: This posthocsubgroup analysis included 216 individuals with T2DM in Egypt with a mean age of 52.7 (±9.8) years. The mean body weight and bodymass index (BMI) were 86.8 (±13.6) and 30.6 (±5.0), respectively. Most included participants were on more than one concomitant OAD (mostly metformin and sulfonylureas). The HbA1c target achievement after 6 months was 27.7%. This figure increased to 51.2% after 12 months. In individuals ³65 years, the HbA1c target achievement after 6 and 12 months was 36% and 52%, respectively. The mean HbA1c% reduced from a baseline value of 9.45 (0.94) to 7.36 (0.60) after 6 months and 6.97 (±0.55) after 12 months of Gla-300 treatment. No major or serious adverse events (AEs) were reported during the follow-up period. Two participants (0.9%) had hypoglyc-emic events, with only oneexperiencing severe hypoglycemia. Conclusion: Insulin treatment with Glar-300 in Egyptian individuals with T2D Muncontrolled on OADs improved glycemic control, and target HbA1c level was achieved in 27.7% after 6 months with a very low risk of hypoglycemia and other treatment-related AEs. People with T2DM who are uncontrolled on OADs may benefit from therapy with Gla-300. Our study results are in line with the results of previously conducted studies.

Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis

Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis

Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study

Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy

Evaluation of glucose metrics in adults with type 1 diabetes switching to Insulin Glargine 300 U/mL: a retrospective, propensity-score matched study

Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades

Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A1chieve Study

A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study

Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach

An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model

Real-World Study on Effectiveness of Insulin Glargine U300 After Oral Antidiabetic Drug Failure in Patients with Type 2 Diabetes in the Gulf Region

Real-world Clinical Effectiveness on Glycaemic Parameters, Safety and Additional Benefits of Glargine U300 (Toujeo®) Initiation after Oral Antidiabetic Drug Failure in Insulin-naïve Patients with type 2 Diabetes Mellitus

Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus

Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis

A 12-Month Prospective Observational Study Assessing the Real-World Clinical Effectiveness and Safety of Insulin Glargine 300 U/mLInitiation After Oral Antidiabetic Drug Failure in Insulin-Naïve Individuals with Type 2 Diabetes Mellitus in Egypt: A Posthoc Subgroup Analysis [ATOS Study]

Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)

Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study